Kazia calls for increased focus on brain cancer research this gbm awareness day

Sydney, july 21, 2021 /prnewswire/ -- kazia therapeutics limited (nasdaq: kzia; asx: kza), a leading drug development company in the field of brain cancer, today recognizes glioblastoma (gbm) awareness day and calls for a greater focus on research from industry, academia, and government in order to better treat the disease. gbm is the most common and most aggressive form of primary brain cancer, and it is expected that approximately 13,000 americans will receive a gbm diagnosis in 2021.
KZIA Ratings Summary
KZIA Quant Ranking